Skip to main content

Advertisement

SpringerLink
Log in

Insulin-like growth factor binding proteins and breast cancer

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Burrows C, Holly JM, Laurence NJ, Vernon EG, Carter JV, Clark MA et al (2006) Insulin-like growth factor binding protein 3 has opposing actions on malignant and nonmalignant breast epithelial cells that are each reversible and dependent upon cholesterol-stabilized integrin receptor complexes. 1. Endocrinology 147(7):3484–3500

    PubMed  CAS  Google Scholar 

  2. Sachdev D, Yee D (2001) The IGF system and breast cancer. Endocr Relat Cancer 8(3):197–209

    PubMed  CAS  Google Scholar 

  3. Marshman E, Streuli CH (2002) Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function. Breast Cancer Res 4(6):231–239

    PubMed  CAS  Google Scholar 

  4. Clemmons DR, Cascieri MA, Camacho-Hubner C, McCusker RH, Bayne ML (1990) Discrete alterations of the insulin-like growth factor I molecule which alter its affinity for insulin-like growth factor-binding proteins result in changes in bioactivity. J Biol Chem 265(21):12210–12216

    PubMed  CAS  Google Scholar 

  5. Gershtein ES, Shatskaya VA, Ermilova VD, Kushlinsky NE, Krasil’nikov MA (1999) Phosphatidylinositol 3-kinase expression in human breast cancer. Clin Chim Acta 287(1–2):59–67

    PubMed  CAS  Google Scholar 

  6. Ram TG, Dilts CA, Dziubinski ML, Pierce LJ, Ethier SP (1996) Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2. Mol Carcinog 15(3):227–238

    PubMed  CAS  Google Scholar 

  7. Zhou X, Tan M, Stone HV, Klos KS, Lan KH, Yang Y et al (2004) Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10(20):6779–6788

    PubMed  CAS  Google Scholar 

  8. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM et al (2004) Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 10(23):8059–8067

    PubMed  CAS  Google Scholar 

  9. Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M et al (2001) The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 28(5, suppl. 16):125–141

    PubMed  CAS  Google Scholar 

  10. Mills GB, Lu Y, Kohn EC (2001) Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci USA 98(18):10031–10033

    PubMed  CAS  Google Scholar 

  11. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275(5308):1943–1947

    PubMed  CAS  Google Scholar 

  12. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL et al (1999) Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155(4):1253–1260

    PubMed  CAS  Google Scholar 

  13. Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JF, Ellis IO (2004) The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 204(1):93–100

    PubMed  CAS  Google Scholar 

  14. Janes PW, Daly RJ, deFazio A, Sutherland RL (1994) Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 9(12):3601–3608

    PubMed  CAS  Google Scholar 

  15. Kato S, Masuhiro Y, Watanabe M, Kobayashi Y, Takeyama KI, Endoh H et al (2000) Molecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways. Genes Cells 5(8):593–601

    PubMed  CAS  Google Scholar 

  16. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC (1997) Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99(7):1478–1483

    PubMed  CAS  Google Scholar 

  17. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R et al (2004) Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100(3):499–506

    PubMed  CAS  Google Scholar 

  18. Zhang CC, Shapiro DJ (2000) Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis. 2. J Biol Chem 275(1):479–486

    PubMed  CAS  Google Scholar 

  19. Kim MS, Lee EJ, Kim HR, Moon A (2003) p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells 46. Cancer Res 63(17):5454–5461

    PubMed  CAS  Google Scholar 

  20. Gee JM, Barroso AF, Ellis IO, Robertson JF, Nicholson RI (2000) Biological and clinical associations of c-jun activation in human breast cancer. 1. Int J Cancer 89(2):177–186

    PubMed  CAS  Google Scholar 

  21. Vuori K, Ruoslahti E (1994) Association of insulin receptor substrate-1 with integrins. Science 266(5190):1576–1578

    PubMed  CAS  Google Scholar 

  22. Woodward TL, Xie J, Fendrick JL, Haslam SZ (2000) Proliferation of mouse mammary epithelial cells in vitro: interactions among epidermal growth factor, insulin-like growth factor I, ovarian hormones, and extracellular matrix proteins. 1. Endocrinology 141(10):3578–3586

    PubMed  CAS  Google Scholar 

  23. Hovey RC, Mackenzie DD, McFadden TB (1998) The proliferation of mouse mammary epithelial cells in response to specific mitogens is modulated by the mammary fat pad in vitro. In Vitro Cell Dev Biol Anim 34(5):385–392

    PubMed  CAS  Google Scholar 

  24. Deeks S, Richards J, Nandi S (1988) Maintenance of normal rat mammary epithelial cells by insulin and insulin-like growth factor. 1. Exp Cell Res 174(2):448–460

    PubMed  CAS  Google Scholar 

  25. Shamay A, Cohen N, Niwa M, Gertler A (1988) Effect of insulin-like growth factor I on deoxyribonucleic acid synthesis and galactopoiesis in bovine undifferentiated and lactating mammary tissue in vitro. Endocrinology 123(2):804–809

    PubMed  CAS  Google Scholar 

  26. Ruan W, Kleinberg DL (1999) Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology 140(11):5075–5081

    PubMed  CAS  Google Scholar 

  27. Farrelly N, Lee YJ, Oliver J, Dive C, Streuli CH (1999) Extracellular matrix regulates apoptosis in mammary epithelium through a control on insulin signaling. J Cell Biol 144(6):1337–1348

    PubMed  CAS  Google Scholar 

  28. Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR, Rosen JM (1996) Targeted expression of des(1–3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology 137(1):321–330

    PubMed  CAS  Google Scholar 

  29. Moorehead RA, Fata JE, Johnson MB, Khokha R (2001) Inhibition of mammary epithelial apoptosis and sustained phosphorylation of Akt/PKB in MMTV-IGF-II transgenic mice. Cell Death Differ 8(1):16–29

    PubMed  CAS  Google Scholar 

  30. Neuenschwander S, Schwartz A, Wood TL, Roberts CT Jr, Hennighausen L, LeRoith D (1996) Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J Clin Invest 97(10):2225–2232

    PubMed  CAS  Google Scholar 

  31. Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ (2001) Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 21(6):2203–2212

    PubMed  CAS  Google Scholar 

  32. Schwertfeger KL, Richert MM, Anderson SM (2001) Mammary gland involution is delayed by activated Akt in transgenic mice. Mol Endocrinol 15(6):867–881

    PubMed  CAS  Google Scholar 

  33. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B et al (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer 98. Lancet 351(9113):1393–1396

    PubMed  CAS  Google Scholar 

  34. Vadgama JV, Wu Y, Datta G, Khan H, Chillar R (1999) Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 57(4):330–340

    PubMed  CAS  Google Scholar 

  35. Renehan AG, Zwahlen M, Minder C, O’dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363(9418):1346–1353

    PubMed  CAS  Google Scholar 

  36. Renehan AG, Harvie M, Howell A (2006) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. 1. Endocr Relat Cancer 13(2):273–278

    PubMed  CAS  Google Scholar 

  37. Paik S (1992) Expression of IGF-I and IGF-II mRNA in breast tissue. 8. Breast Cancer Res Treat 22(1):31–38

    PubMed  CAS  Google Scholar 

  38. Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ et al (1989) Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. 2. Mol Endocrinol 3(3):509–517

    Article  PubMed  CAS  Google Scholar 

  39. Toropainen EM, Lipponen PK, Syrjanen KJ (1995) Expression of insulin-like growth factor II in female breast cancer as related to established prognostic factors and long-term prognosis. 1. Anticancer Res 15(6B):2669–2674

    PubMed  CAS  Google Scholar 

  40. Hwa V, Oh Y, Rosenfeld RG (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily. 1. Endocr Rev 20(6):761–787

    PubMed  CAS  Google Scholar 

  41. LeRoith D, Baserga R, Helman L, Roberts CT Jr (1995) Insulin-like growth factors and cancer. Ann Intern Med 122(1):54–59

    PubMed  CAS  Google Scholar 

  42. Burger AM, Leyland-Jones B, Banerjee K, Spyropoulos DD, Seth AK (2005) Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur J Cancer 41(11):1515–1527

    PubMed  CAS  Google Scholar 

  43. Kostecka Y, Blahovec J (1999) Insulin-like growth factor binding proteins and their functions (minireview). 2. Endocr Regul 33(2):90–94

    PubMed  CAS  Google Scholar 

  44. Miyamoto S, Yano K, Sugimoto S, Ishii G, Hasebe T, Endoh Y et al (2004) Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. 2. Cancer Res 64(2):665–671

    PubMed  CAS  Google Scholar 

  45. Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. 1. Endocr Rev 23(6):824–854

    PubMed  CAS  Google Scholar 

  46. Schedlich LJ, Young TF, Firth SM, Baxter RC (1998) Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. 1. J Biol Chem 273(29):18347–18352

    PubMed  CAS  Google Scholar 

  47. Reinecke M, Collet C (1998) The phylogeny of the insulin-like growth factors. 1. Int Rev Cytol 183:1–94

    Article  PubMed  CAS  Google Scholar 

  48. Forbes BE, Turner D, Hodge SJ, McNeil KA, Forsberg G, Wallace JC (1998) Localization of an insulin-like growth factor (IGF) binding site of bovine IGF binding protein-2 using disulfide mapping and deletion mutation analysis of the C-terminal domain 16. J Biol Chem 273(8):4647–4652

    PubMed  CAS  Google Scholar 

  49. Neumann GM, Marinaro JA, Bach LA (1998) Identification of O-glycosylation sites and partial characterization of carbohydrate structure and disulfide linkages of human insulin-like growth factor binding protein 6. 2. Biochemistry 37(18):6572–6585

    PubMed  CAS  Google Scholar 

  50. Coverley JA, Baxter RC (1997) Phosphorylation of insulin-like growth factor binding proteins. 2. Mol Cell Endocrinol 128(1–2):1–5

    PubMed  CAS  Google Scholar 

  51. Coverley JA, Baxter RC (1995) Regulation of insulin-like growth factor (IGF) binding protein-3 phosphorylation by IGF-I. 3. Endocrinology 136(12):5778–5781

    PubMed  CAS  Google Scholar 

  52. Hashimoto R, Ono M, Fujiwara H, Higashihashi N, Yoshida M, Enjoh-Kimura T et al (1997) Binding sites and binding properties of binary and ternary complexes of insulin-like growth factor-II (IGF-II), IGF-binding protein-3, and acid-labile subunit. 3. J Biol Chem 272(44):27936–27942

    PubMed  CAS  Google Scholar 

  53. Lalou C, Lassarre C, Binoux M (1996) A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 137(8):3206–3212

    PubMed  CAS  Google Scholar 

  54. Yamanaka Y, Fowlkes JL, Wilson EM, Rosenfeld RG, Oh Y (1999) Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. 1. Endocrinology 140(3):1319–1328

    PubMed  CAS  Google Scholar 

  55. Jones JI, Gockerman A, Busby WH Jr, Wright G, Clemmons DR (1993) Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. 3. Proc Natl Acad Sci USA 90(22):10553–10557

    PubMed  CAS  Google Scholar 

  56. Rajaram S, Baylink DJ, Mohan S (1997) Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. 1. Endocr Rev 18(6):801–831

    PubMed  CAS  Google Scholar 

  57. Radulescu RT (1994) Nuclear localization signal in insulin-like growth factor-binding protein type 3. 3. Trends Biochem Sci 19(7):278

    PubMed  CAS  Google Scholar 

  58. Wraight CJ, Liepe IJ, White PJ, Hibbs AR, Werther GA (1998) Intranuclear localization of insulin-like growth factor binding protein-3 (IGFBP-3) during cell division in human keratinocytes. 3. J Invest Dermatol 111(2):239–242

    PubMed  CAS  Google Scholar 

  59. Li W, Fawcett J, Widmer HR, Fielder PJ, Rabkin R, Keller GA (1997) Nuclear transport of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in opossum kidney cells. 4. Endocrinology 138(4):1763–1766

    PubMed  CAS  Google Scholar 

  60. Perks CM, Newcomb PV, Norman MR, Holly JM (1999) Effect of insulin-like growth factor binding protein-1 on integrin signalling and the induction of apoptosis in human breast cancer cells. 6. J Mol Endocrinol 22(2):141–150

    PubMed  CAS  Google Scholar 

  61. Rajah R, Valentinis B, Cohen P (1997) Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. 1. J Biol Chem 272(18):12181–12188

    PubMed  CAS  Google Scholar 

  62. Andre F, Rigot V, Thimonier J, Montixi C, Parat F, Pommier G et al (1999) Integrins and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells. 1. Int J Cancer 83(4):497–505

    PubMed  CAS  Google Scholar 

  63. Imai Y, Busby WH Jr, Smith CE, Clarke JB, Garmong AJ, Horwitz GD et al (1997) Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture. 2. J Clin Invest 100(10):2596–2605

    PubMed  CAS  Google Scholar 

  64. Firth SM, Baxter RC (1999) Characterisation of recombinant glycosylation variants of insulin-like growth factor binding protein-3. 4. J Endocrinol 160(3):379–387

    PubMed  CAS  Google Scholar 

  65. Jones JI, D’Ercole AJ, Camacho-Hubner C, Clemmons DR (1991) Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: effects on affinity for IGF-I. 1. Proc Natl Acad Sci USA 88(17):7481–7485

    PubMed  CAS  Google Scholar 

  66. Nickerson T, Huynh H, Pollak M (1997) Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. 3. Biochem Biophys Res Commun 237(3):690–693

    PubMed  CAS  Google Scholar 

  67. Smits VA, Medema RH (2001) Checking out the G(2)/M transition. 3. Biochim Biophys Acta 1519(1–2):1–12

    PubMed  CAS  Google Scholar 

  68. Perks CM, McCaig C, Clarke JB, Clemmons DR, Holly JM (2002) A non-IGF binding mutant of IGFBP-3 modulates cell function in breast epithelial cells. 5. Biochem Biophys Res Commun 294(5):988–994

    PubMed  CAS  Google Scholar 

  69. Perks CM, Bowen S, Gill ZP, Newcomb PV, Holly JM (1999) Differential IGF-independent effects of insulin-like growth factor binding proteins (1–6) on apoptosis of breast epithelial cells. 1. J Cell Biochem 75(4):652–664

    PubMed  CAS  Google Scholar 

  70. Butt AJ, Firth SM, King MA, Baxter RC (2000) Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. 3. J Biol Chem 275(50):39174–39181

    PubMed  CAS  Google Scholar 

  71. Rajah R, Lee KW, Cohen P (2002) Insulin-like growth factor binding protein-3 mediates tumor necrosis factor-alpha-induced apoptosis: role of Bcl-2 phosphorylation. 1. Cell Growth Differ 13(4):163–171

    PubMed  CAS  Google Scholar 

  72. Figueroa JA, Jackson JG, McGuire WL, Krywicki RF, Yee D (1993) Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. 6. J Cell Biochem 52(2):196–205

    PubMed  CAS  Google Scholar 

  73. Clemmons DR, Camacho-Hubner C, Coronado E, Osborne CK (1990) Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. 2. Endocrinology 127(6):2679–2686

    Article  PubMed  CAS  Google Scholar 

  74. Pekonen F, Nyman T, Ilvesmaki V, Partanen S (1992) Insulin-like growth factor binding proteins in human breast cancer tissue. 1. Cancer Res 52(19):5204–5207

    PubMed  CAS  Google Scholar 

  75. Yee D, Favoni RE, Lippman ME, Powell DR (1991) Identification of insulin-like growth factor binding proteins in breast cancer cells. 2. Breast Cancer Res Treat 18(1):3–10

    PubMed  CAS  Google Scholar 

  76. Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS (1998) Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. 2. Epidemiology 9(5):570–573

    PubMed  CAS  Google Scholar 

  77. Bruning PF, Van DJ, Bonfrer JM, Van Noord PA, Korse CM, Linders TC et al (1995) Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. 4. Int J Cancer 62(3):266–270

    PubMed  CAS  Google Scholar 

  78. Baxter RC (2001) What is the significance of IGF-binding protein-3 proteolysis in the circulation? 2. J Clin Endocrinol Metab 86(10):5087–5088

    PubMed  CAS  Google Scholar 

  79. Oh Y (1998) IGF-independent regulation of breast cancer growth by IGF binding proteins. Breast Cancer Res Treat 47(3):283–293

    PubMed  CAS  Google Scholar 

  80. Fowler CA, Perks CM, Newcomb PV, Savage PB, Farndon JR, Holly JM (2000) Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells. 2. Int J Cancer 88(3):448–453

    PubMed  CAS  Google Scholar 

  81. Gill ZP, Perks CM, Newcomb PV, Holly JM (1997) Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. 4. J Biol Chem 272(41):25602–25607

    PubMed  CAS  Google Scholar 

  82. Huynh H, Yang X, Pollak M (1996) Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. 5. J Biol Chem 271(2):1016–1021

    PubMed  CAS  Google Scholar 

  83. Martin JL, Weenink SM, Baxter RC (2003) Insulin-like growth factor-binding protein-3 potentiates epidermal growth factor action in MCF-10A mammary epithelial cells: involvement of p44/42 and p38 mitogen-activated protein kinases. 1. J Biol Chem 278(5):2969–2976

    PubMed  CAS  Google Scholar 

  84. Butt AJ, Martin JL, Dickson KA, McDougall F, Firth SM, Baxter RC (2004) Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signaling. 1. J Clin Endocrinol Metab 89(4):1950–1956

    PubMed  CAS  Google Scholar 

  85. Conover CA (1991) Glycosylation of insulin-like growth factor binding protein-3 (IGFBP-3) is not required for potentiation of IGF-I action: evidence for processing of cell-bound IGFBP-3. 1. Endocrinology 129(6):3259–3268

    PubMed  CAS  Google Scholar 

  86. Conover CA (1992) Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: studies of underlying mechanism 11. Endocrinology 130(6):3191–3199

    PubMed  CAS  Google Scholar 

  87. De Mellow JS, Baxter RC (1988) Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblasts. 1. Biochem Biophys Res Commun 156(1):199–204

    PubMed  Google Scholar 

  88. McCaig C, Perks CM, Holly JM (2002) Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. 2. J Cell Sci 115(pt 22):4293–4303

    PubMed  CAS  Google Scholar 

  89. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL et al (2002) Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression 5. Eur J Cancer 38(18):2362–2370

    PubMed  CAS  Google Scholar 

  90. Jones JI, Gockerman A, Busby WH Jr, Camacho-Hubner C, Clemmons DR (1993) Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. 4. J Cell Biol 121(3):679–687

    PubMed  CAS  Google Scholar 

  91. Oh Y, Muller HL, Lamson G, Rosenfeld RG (1993) Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells: cell surface binding and growth inhibition. J Biol Chem 268(20):14964–14971

    PubMed  CAS  Google Scholar 

  92. Martin JL, Ballesteros M, Baxter RC (1992) Insulin-like growth factor-I (IGF-I) and transforming growth factor-beta 1 release IGF-binding protein-3 from human fibroblasts by different mechanisms. 1. Endocrinology 131(4):1703–1710

    PubMed  CAS  Google Scholar 

  93. Firth SM, Ganeshprasad U, Baxter RC (1998) Structural determinants of ligand and cell surface binding of insulin-like growth factor-binding protein-3. 2. J Biol Chem 273(5):2631–2638

    PubMed  CAS  Google Scholar 

  94. Leal SM, Liu Q, Huang SS, Huang JS (1997) The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. 5. J Biol Chem 272(33):20572–20576

    PubMed  CAS  Google Scholar 

  95. Fanayan S, Firth SM, Baxter RC (2002) Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells: relationship to transforming growth factor-beta 1 signaling. 1. J Biol Chem 277(9):7255–7261

    PubMed  CAS  Google Scholar 

  96. McCaig C, Fowler CA, Laurence NJ, Lai T, Savage PB, Holly JM et al (2002) Differential interactions between IGFBP-3 and transforming growth factor-beta (TGF-beta) in normal vs cancerous breast epithelial cells. Br J Cancer 86(12):1963–1969

    PubMed  CAS  Google Scholar 

  97. Butt AJ, Fraley KA, Firth SM, Baxter RC (2002) IGF-binding protein-3-induced growth inhibition and apoptosis do not require cell surface binding and nuclear translocation in human breast cancer cells. 1. Endocrinology 143(7):2693–2699

    PubMed  CAS  Google Scholar 

  98. Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D (1996) Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. 2. J Natl Cancer Inst 88(9):601–606

    PubMed  CAS  Google Scholar 

  99. Rocha RL, Hilsenbeck SG, Jackson JG, VanDenBerg CL, Weng C, Lee AV et al (1997) Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. 1. Clin Cancer Res 3(1):103–109

    PubMed  CAS  Google Scholar 

  100. Yoshida N, Omoto Y, Inoue A, Eguchi H, Kobayashi Y, Kurosumi M et al (2004) Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. 3. Cancer Sci 95(6):496–502

    PubMed  CAS  Google Scholar 

  101. McCarthy K, Laban CA, Bustin SA, Ogunkolade BW, Carpenter R, Jenkins PJ (2003) Expression of insulin-like growth factor binding protein-3 (IGFBP-3) is down regulated in breast cancer compared to normal breast tissue. Endocrine Abstracts 2002:4

  102. Hao X, Sun B, Hu L, Lahdesmaki H, Dunmire V, Feng Y et al (2004) Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 100(6):1110–1122

    PubMed  CAS  Google Scholar 

  103. Vestey SB, Perks CM, Sen C, Calder CJ, Holly JM, Winters ZE (2005) Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome. 2. Breast Cancer Res 7(1):R119–R129

    PubMed  CAS  Google Scholar 

  104. Kato MV (2000) A secreted tumor-suppressor, mac25, with activin-binding activity. Mol Med 6(2):126–135

    PubMed  CAS  Google Scholar 

  105. Jeruss JS, Sturgis CD, Rademaker AW, Woodruff TK (2003) Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. 1. Cancer Res 63(13):3783–3790

    PubMed  CAS  Google Scholar 

  106. St CB, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E et al (2000) Genes expressed in human tumor endothelium. 3. Science 289(5482):1197–1202

    Google Scholar 

  107. Ahmed S, Yamamoto K, Sato Y, Ogawa T, Herrmann A, Higashi S et al (2003) Proteolytic processing of IGFBP-related protein-1 (TAF/angiomodulin/mac25) modulates its biological activity. 9. Biochem Biophys Res Commun 310(2):612–618

    PubMed  CAS  Google Scholar 

  108. Kanemitsu N, Kato MV, Miki T, Komatsu S, Okazaki Y, Hayashizaki Y et al (2000) Characterization of the promoter of the murine mac25 gene. Biochem Biophys Res Commun 279(1):251–257

    PubMed  CAS  Google Scholar 

  109. Komatsu S, Okazaki Y, Tateno M, Kawai J, Konno H, Kusakabe M et al (2000) Methylation and downregulated expression of mac25/insulin-like growth factor binding protein-7 is associated with liver tumorigenesis in SV40T/t antigen transgenic mice, screened by restriction landmark genomic scanning for methylation (RLGS-M). 8. Biochem Biophys Res Commun 267(1):109–117

    PubMed  CAS  Google Scholar 

  110. Burger AM, Zhang X, Li H, Ostrowski JL, Beatty B, Venanzoni M et al (1998) Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. 9. Oncogene 16(19):2459–2467

    PubMed  CAS  Google Scholar 

  111. Landberg G, Ostlund H, Nielsen NH, Roos G, Emdin S, Burger AM et al (2001) Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors. 7. Oncogene 20(27):3497–3505

    PubMed  CAS  Google Scholar 

  112. Seth A, Kitching R, Landberg G, Xu J, Zubovits J, Burger AM (2003) Gene expression profiling of ductal carcinomas in situ and invasive breast tumors. 9. Anticancer Res 23(3A):2043–2051

    PubMed  CAS  Google Scholar 

  113. Swisshelm K, Ryan K, Tsuchiya K, Sager R (1995) Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid. 1. Proc Natl Acad Sci USA 92(10):4472–4476

    PubMed  CAS  Google Scholar 

  114. Firth SM, Fanayan S, Benn D, Baxter RC (1998) Development of resistance to insulin-like growth factor binding protein-3 in transfected T47D breast cancer cells. 3. Biochem Biophys Res Commun 246(2):325–329

    PubMed  CAS  Google Scholar 

  115. Wilson HM, Birnbaum RS, Poot M, Quinn LS, Swisshelm K (2002) Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. 1. Cell Growth Differ 13(5):205–213

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Breast Surgery, St Georges Hospital NHS Trust, Blackshaw Road, Tooting, London, SW17 OQT, UK

    Ashok Subramanian, Anup Sharma & Kefah Mokbel

  2. The Brunel Institute of Genetics and Pharmacogenetics, London, UK

    Kefah Mokbel

  3. 24 Northcote Road, New Malden, Surrey, KT3 3HG, England, UK

    Ashok Subramanian

Authors
  1. Ashok Subramanian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anup Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kefah Mokbel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ashok Subramanian.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Subramanian, A., Sharma, A. & Mokbel, K. Insulin-like growth factor binding proteins and breast cancer. Breast Cancer Res Treat 107, 181–194 (2008). https://doi.org/10.1007/s10549-007-9549-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-007-9549-0

Keywords

Search

Navigation